Welcome! Thank you for subscribing to the Earnings360 newsletter, your daily source for quarterly earnings news and updates.
Each morning edition contains a wrap-up of today's pre-market earnings announcements and yesterday's earnings announcements after the closing bell.
Please take a moment to confirm your subscription below so we can ensure these updates reach your inbox.
Confirm Your Subscription Here
The Earnings360 Team
Further Reading from MarketBeat Media Why GRAIL Stock Could Be Biotech's Next Big BreakoutWritten by Bridget Bennett. Published 11/19/2025. 
Key Points - Insider buying is a reliable signal in market pullbacks, offering long-term confidence amid short-term volatility.
- Biotech stock GRAIL is one to watch, with its breakthrough cancer detection technology nearing FDA approval.
- Despite economic concerns, the American Dream is still attainable through long-term investing, saving, and strategic financial choices.
Retail investors are understandably on edge after several sessions of market volatility. But bestselling author and Oxford Club strategist Alexander Green, in his new book The American Dream, says we’re still in one of the best times in history to build wealth—especially if you think long term and stick to time-tested principles. According to Green, this pullback isn't as severe as it may feel. "Just last Wednesday, the Dow hit an all-time high," he noted, explaining that recent selling pressure has more to do with valuation concerns and interest rate uncertainty than any fundamental breakdown. Why the Market Pulled Back Make sure you watch this critical video message …
Because this Cyber Weekend only ...
I am sharing what I believe could be a much better way to tap into this massive flood of money …
Without buying a single coin ...
For only $19. That's a savings of 85%! Click here now before it's too late. Green attributes the dip to two main concerns. First, investors are starting to question elevated tech and AI valuations, particularly as earnings season brings those expectations into focus. Second, inflation readings and slower hiring have reduced hopes that the Fed will cut rates in December. With the central bank emphasizing a "data-dependent" stance, markets are less certain that relief is coming this year. Why Selling Now Might Be the Wrong Move Instead of trying to predict next week’s moves, Green encourages investors to zoom out. He calls himself "a long-term optimist," and points out that historically the market’s trend has been up and to the right. Short-term traders may want to be cautious, but for long-term investors these dips are often opportunities to buy high-quality stocks at more attractive prices. Insider Buying Can Point the Way One of the most reliable indicators in times like these is insider buying. Green suggests that when officers and directors—people with access to non-public financial information—are putting money into their own companies, that’s worth noting. He recommends tracking insider trading activity to see which stocks corporate executives are buying, not just selling. While insiders aren’t always right, their actions can be a useful signal when markets are in flux. A Biotech Breakout to Watch: GRAIL One sector Green is focused on right now is biotech, where artificial intelligence is helping accelerate drug development and reduce costs. He highlighted one company in particular: GRAIL (NASDAQ: GRAL). Spun off from Illumina, GRAIL developed the Galleri Test, which can detect more than 50 types of cancer from a simple blood draw. Green has used the test himself and calls it "a good feeling" to know you’re clear for so many deadly diseases—especially ones like pancreatic cancer that often go undetected until late stages. With FDA fast-track status and potential for insurance reimbursement, Green sees GRAIL’s roughly $3 billion market cap as just a starting point. The Biotech Risk—and Big Pharma's Appetite Of course, biotech carries risk: most drug candidates never make it through all trial phases. Still, larger pharmaceutical companies like Merck (NYSE: MRK), Pfizer (NYSE: PFE), and Bristol Myers (NYSE: BMY) are actively acquiring promising small caps to replace expiring patents. Green pointed to Johnson & Johnson (NYSE: JNJ) as a recent example: the company invested in a private prostate cancer drug before FDA approval—underscoring how aggressive Big Pharma can be when trials look promising. He believes biotech is especially compelling now because healthcare is recession-resistant. People seek treatment regardless of the economic cycle. For investors wanting to weather volatility, sectors like healthcare, utilities, consumer staples, and food companies offer steady demand—and generally less drama than high-flying AI names. The American Dream Is Still Possible—But Mindset Matters Despite economic challenges, Green argues the American Dream is far from dead. He wrote The American Dream to counter the narrative that it’s out of reach, noting he was surprised to see polls showing nearly 70% of Americans believe it’s no longer attainable. The reality, he says, is that with access to low-cost investment tools, no-commission trading, and abundant information, building wealth has never been more accessible. The challenge is knowing what to do—and having the discipline to do it. He breaks it down simply: if a 25-year-old invests $190 per month in an S&P 500 index fund, they could have $1 million by age 65—tax-free in a Roth IRA. No extreme frugality required. "You could eat out, take trips, and still build wealth," Green says—as long as you save consistently and leave that money to compound. Creative Solutions for Today's Housing Market Housing may feel out of reach, but Green says there are still ways in. Mortgage rates have doubled and prices are up since the pandemic, but creative options exist. He shares his personal story of buying two houses with no money down by working directly with motivated sellers and assuming their mortgages—a method often called a "contract for deed." It might not get you the perfect house immediately, but it can help you start building equity sooner. Stay Focused on the Long Game Volatile markets come and go. What matters is how you respond. Whether it’s tracking insider moves, exploring high-upside sectors like biotech, or simply believing in your ability to build a financial future, Green’s message is clear: the American Dream is still within reach. Keep your eyes on it—and take the next right step.
| 
